Lymphoma Hub

A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia. #lymsm

[Lymphoma Hub @lymphomahub]

The Lymphoma Hub virtual symposium, titled ‘Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors’, was chaired by Gilles Salles and featured presentations by Susan O’Brien, Farrukh Awan, and Francesc Bosch.

Catch up here: https://t.co/5WutWeucmu

#MedEd #MedNews #leusm #lymsm

Intended for healthcare professionals. Independently supported by Eli Lilly and Company. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

New publication 📝 Real-world data, published in @TheLancetHaem, show fatigue (87%), decreased appetite (83%), and insomnia (79%) were the most common general, GI, and neuropsychiatric AEs reported by patients at Day 10 post-CAR T-cell infusion.

Learn more about aggressive B-cell lymphomas: https://t.co/I9iW2Wdmgi

#lymsm #Lymphoma #MedNews #MedEd

[Lymphoma Hub @lymphomahub]

🎧 During the Lymphoma Hub virtual symposium, titled Optimizing treatment for CLL with BTK inhibitors, Francesc Bosch led a case-based presentation and panel discussion on optimizing chronic lymphocytic leukemia management in a changing landscape.

Listen here: https://t.co/jiHN56COqy

#leusm #lymsm #MedEd #MedNews

Intended for healthcare professionals only. Independently supported by Eli Lilly. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

🎥 During the Lymphoma Hub virtual symposium, titled Optimizing treatment for CLL with BTK inhibitors, Francesc Bosch led a case-based presentation and panel discussion. The panel discussed the positioning of non-covalent BTK inhibitors in CLL treatment.

Watch the full video here: https://t.co/zU2YsEris6

#leusm #lymsm #MedEd #MedNews

[Lymphoma Hub @lymphomahub]

New publication 📝 Results from a phase II study, published in @sigtrans_sttt, show that abexinostat achieved an ORR of 69.5% and a CR rate of 14.6% in patients with R/R FL.

Learn more about FL: https://t.co/yL6up3SBCv

#FollicularLymphoma #Lymphoma #MedNews #MedEd

[Lymphoma Hub @lymphomahub]

🎧 During the Lymphoma Hub virtual symposium, titled Optimizing treatment for CLL with BTK inhibitors, Farrukh Awan delivered a presentation on BTK inhibitors in practice: Treatment selection and emerging clinical evidence.

Listen here: https://t.co/GOfeozslYd

#leusm #lymsm #MedEd #MedNews

Intended for healthcare professionals only. Independently supported by Eli Lilly. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

New publication 📝Results from the phase I/II TRANSCEND CLL 004 trial, published in Blood, show liso-cel + ibrutinib achieved a CR/CRi rate of 45% and ORR of 86% in patients with R/R CLL/SLL.

Learn more about CLL/SLL: https://t.co/VKNO2EHs5X

#Lymphoma #Lymsm #MedNews #MedEd

[Lymphoma Hub @lymphomahub]

🎥 During the Lymphoma Hub virtual symposium, titled Optimizing treatment for CLL with BTK inhibitors, Farrukh Awan highlighted results from the BRUIN CLL-322 trial of fixed-duration pirtobrutinib + venetoclax + rituximab (PVR) vs venetoclax + rituximab (VR) in patients with R/R CLL.

Watch the full video here: https://t.co/6OLzZIgmPd

#leusm #lymsm #MedEd #MedNews @awandoc

Intended for healthcare professionals. Independently supported by Eli Lilly and Company. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

🚨 News 🚨

@US_FDA clears an IND application for prizloncabtagene autoleucel (prizlon-cel), an anti-CD20/CD19 bispecific CAR T-cell therapy, for the treatment of R/R LBCL.

Read more: https://t.co/pUNdf28EA7

#lymsm #leusm #MedEd #MedNews

[Lymphoma Hub @lymphomahub]

🎧 During the Lymphoma Hub virtual symposium, titled Optimizing treatment for CLL with BTK inhibitors, Susan O’Brien delivered a presentation on BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs.

Listen here: https://t.co/5q9xsYUBqc

#leusm #lymsm #MedEd #MedNews

Intended for healthcare professionals only. Independently supported by Eli Lilly. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

New publication 📝 Results from the phase III MATRix/IELSG43 trial, published in @TheLancet, show HCT–ASCT significantly improved 3-year progression-free survival vs R-DeVIC consolidation in newly diagnosed PCNSL (78% vs 51%; p = 0.0003).

Learn more about PCNSL: https://t.co/axPHRRDMCM

#Lymphoma #Lymphomasm #MedNews #MedEd

[Lymphoma Hub @lymphomahub]

🎥 During the Lymphoma Hub virtual symposium, titled Optimizing treatment for CLL with BTK inhibitors, Susan O’Brien discussed the impact of BTKi resistance mutations in patients with CLL and strategies to overcome them.

Watch the full video here: https://t.co/QxsY9Dr9Be

#leusm #lymsm #MedEd #MedNews

Intended for healthcare professionals. Independently supported by Eli Lilly and Company. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

New publication 📝 Results from the phase II EPCORE DLBCL-3 trial, published in @TheLancetHaem, show fixed-duration epcoritamab monotherapy achieved a CR rate of 57.6% in older patients with ND DLBCL ineligible for anthracycline-based chemoimmunotherapy.

Learn more about DLBCL: https://t.co/KcW0XXpdjK

#lymsm #Lymphoma #MedNews #MedEd

[Lymphoma Hub @lymphomahub]

What factors influence treatment decisions in patients with CLL?

During the Lymphoma Hub virtual symposium, Francesc Bosch discussed patient cases and led a panel discussion on optimizing CLL management in a changing landscape.

Watch here: https://t.co/zU2YsEris6

#leusm #lymsm #MedEd #MedNews

Intended for healthcare professionals only. Independently supported by Eli Lilly. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

🚨NEWS🚨

@NICEComms recommends acalabrutinib + bendamustine + rituximab for patients with MCL and acalabrutinib + venetoclax for patients with CLL.

Read more: https://t.co/e5OP0dlf82

#lymsm #leusm #MedEd #MedNews

[Lymphoma Hub @lymphomahub]

🎥 During the Lymphoma Hub virtual symposium, titled Optimizing treatment for CLL with BTK inhibitors, Francesc Bosch led a case-based presentation and panel discussion on optimizing CLL management in a changing landscape.

Watch here: https://t.co/zU2YsEris6

#leusm #lymsm #MedEd #MedNews

Intended for healthcare professionals only. Independently supported by Eli Lilly. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

What is the clinical evidence for the use of BTKi in patients with CLL? During the Lymphoma Hub virtual symposium, Farrukh Awan discussed key trial results for BTKi in CLL.

Watch here: https://t.co/6OLzZIgmPd

#leusm #lymsm #MedEd #MedNews

Intended for healthcare professionals only. Independently supported by Eli Lilly. Funders are allowed no influence

[Lymphoma Hub @lymphomahub]

New publication 📝 Updates from the phase I CaDAnCe-101 trial, presented at #EHA2026, share that tacabrutideg demonstrated durable antitumor activity with a manageable safety profile in heavily pretreated R/R CLL/SLL. Grade ≥3 TEAEs occurred in 62.7% of patients, while the ORR was 85.1% across doses and 94.1% in patients receiving 200 mg tacabrutideg (RDFE).

Learn more about CLL: https://t.co/28LlgJxKWH

#MedNews #MedEd

[Lymphoma Hub @lymphomahub]

What are the key mechanisms, clinical considerations, and unmet needs regarding BTKi in CLL? During the Lymphoma Hub virtual symposium, Susan O’Brien provided an overview of the use of BTKi in CLL.

Watch here: https://t.co/QxsY9Dr9Be

#leusm #lymsm #MedEd #MedNews

Intended for healthcare professionals only. Independently supported by Eli Lilly. Funders are allowed no influence.

[Lymphoma Hub @lymphomahub]

New publication 📝 Results from a retrospective analysis, presented at #EHA2026, show that CD20 × CD3 BsAbs are a feasible and effective bridging strategy before CAR T-cell therapy in LBCL.

Learn more from EHA2026: https://t.co/smXWxwBnhl

#lymsm #lymphoma #MedNews #MedEd